Malignant melanoma - Melanoma Malignant
Ko te Melanoma Malignant (Malignant melanoma) he momo mate puku‑puku kiri e puta mai i ngā pūtau melanocytes. I te nuinga o ngā wā ka pā ki ngā waewae i ngā wāhine, ā, i ngā tāne ka puta ki muri. Tata ki te 25 % o ngā melanomas ka puta mai i te nevus. Ko ngā huringa i roto i te nevi e tohu ana i te melanoma ko te pikinga o te rahi, he kopikopiko ngā tapa, he rereke te tae, he whewhe rānei. Ko te take matua o te melanoma ko te whakamārama o te rāma ultraviolet ki te hunga he iti te taumata o te melanin (taupori ma) i te kiri. Ko te rāma UV ka puta mai i te rā, i ngā taputapu tāna rānei. Ko te hunga he maha ngā nevus, he hītori melanoma i ngā mema o te whānau, me te ngoikore o te mahi ārai, ka nui ake te mōrearea ki te melanoma. Mā te whakamahi i te ārai rā, me te karo i te rāma UV, ka taea te aukati i te melanoma. Ko te tikanga, ka tangohia te maimoatanga mā te pokanga. Ki te hunga he mate paku te rahi, ka whakamātauhia ngā kōpuku lymph mō te horapa (metastasis). Ko te nuinga o ngā tāngata ka ora mēnā kāore he metastasis. Mō te hunga kua horapa te melanoma, ka pai ake te oranga mā te rongoā mate, te rongoā kōiora, te whakamārama iraruke, te chemotherapy rānei. Mā te maimoatanga, ko ngā rēti oranga e rima tau i te United States, ko te 99 % i waenga i te hunga e mate ana i te rohe, 65 % i te wā kua horapa te mate ki ngā kōpuku lymph, me te 25 % i waenga i te hunga kua horapa tawhiti. Ko te Melanoma te momo tino kino o te mate puku‑puku kiri. Ko Ahitereiria me Aotearoa te rēti teitei o te mate puku‑puku o te ao. Ka puta te rēti teitei o te mate puku‑puku ki te Raki o Ūropi me Amerika Te Tai Tokerau. He iti ake te āhua o te Melanoma ki Ahia, Awherika, me Amerika Latina. I te United States, 1.6 ngā wā ka nui ake te mate melanoma i ngā tāne i ngā wāhine. ○ Ngā tohu me ngā āhuatanga Ko ngā tohu tuatahi o te melanoma ko ngā huringa ki te āhua me te tae o te nevus o nāianei. I te melanoma nodular, ko te āhua o te putunga hou i runga i te kiri. I ngā wāhanga o muri mai o te melanoma, ka patito te nevi, ka pupuhi, ka whakaheke te toto rānei. [A‑Asymmetry] Hangārite te ahua [B‑Borders] Taitapa (he koretaka me ngā tapa me ngā kokonga) [C‑Color] Tae (he rereke me te korikori) [D‑Diameter] Diamita (nui ake i te 6 mm = 0.24 inchi = rite te rahi o te kōmuru pene) [E‑Evolving] Te whanake i roto i te wā cf) Ka tutuki pea te keratosis seborrheic ki ētahi, ki te katoa rānei o ngā paearu ABCD, ka puta he whakaoho teka. Ka taea te metastasis o te melanoma tere, engari he iti iho i te haurima o ngā melanomas ka kitea mō te wā ka huri hei metastatic. Ka kitea ngā metastasis o te melanoma ki te roro, ki ngā turoro, ki te ate, ki ngā wheua, ki te puku, me ngā kōpuku lymph tawhiti rānei. ○ Tātari Ko te titiro ki te wāhi e pā ana ko te tikanga tino noa mō te whakapae he mate puku‑puku. Ko ngā nevus he rereke te tae, te āhua rānei, ka kīia he tohu mate puku‑puku. Ka tirohia e ngā rata ngā nevus katoa, tae atu ki ngā iti iho i te 6 mm te whānui. Ina whakamahia e ngā tohunga kua whakangungua, he pai ake te mahi a dermoscopy ki te tautuhi i ngā mate kino atu i te whakamahi i te kanohi tahanga anake. Ko te tātaritanga mā te kōiora o tētahi reanga kiri he tohu kei te mate puku‑puku pea. ○ Maimoatanga #Mohs surgery Ka tohuhia pea e tō tākuta te whakamārama mō te maimoatanga mēnā kei a koe te wāhanga 3, te wāhanga 4 o te melanoma, kāore e taea te tango mā te pokanga. #Ipilimumab [Yervoy] #Pembrolizumab [Keytruda] #Nivolumab [Opdivo]
☆ AI Dermatology — Free Service
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
He melanoma tata ki te 2.5 cm (1 inihi) me te 1.5 cm (0.6 inihi).
relevance score : -100.0%
ReferencesKo te melanoma he momo pukupuku ka puta i te wā e kino ana ngā melanocytes. Ko ngā melanocytes i ahu mai i te kōhanga neural. Ko te tikanga, ka tupu te melanoma, ehara i te kiri anake, engari ki ētahi atu wāhi e haere ana ngā pūtau neural crest, pērā i te kōpā me te roro. Ko te hunga mate i te wāhanga 0 melanoma, e rima tau te roa o te oranga, 97 % te rātou ora, engari ko te hunga e mate ana i te wāhanga IV, he 10 % noa iho.
A melanoma is a tumor produced by the malignant transformation of melanocytes. Melanocytes are derived from the neural crest; consequently, melanomas, although they usually occur on the skin, can arise in other locations where neural crest cells migrate, such as the gastrointestinal tract and brain. The five-year relative survival rate for patients with stage 0 melanoma is 97%, compared with about 10% for those with stage IV disease.
A melanoma is a tumor produced by the malignant transformation of melanocytes. Melanocytes are derived from the neural crest; consequently, melanomas, although they usually occur on the skin, can arise in other locations where neural crest cells migrate, such as the gastrointestinal tract and brain. The five-year relative survival rate for patients with stage 0 melanoma is 97%, compared with about 10% for those with stage IV disease.
Ko te Cutaneous melanoma (CM) he momo tumo kiri tino kino, he kawenga mō te 90 % o ngā mate pukupuku kiri. Hei whakatika i tēnei, i mahi tahi ngā tohunga o te European Dermatology Forum (EDF), te European Association of Dermato‑Oncology (EADO) me te European Organization for Research and Treatment of Cancer (EORTC).
Cutaneous melanoma (CM) is a highly dangerous type of skin tumor, responsible for 90% of skin cancer deaths. To address this, experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC) had collaborated.
Cutaneous melanoma (CM) is a highly dangerous type of skin tumor, responsible for 90% of skin cancer deaths. To address this, experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC) had collaborated.
Ko te melanoma he momo mate pukupuku kiri, ā, e hono tata ana ki te punaha immune. Ka kitea i te hunga kua pā ki te mate, i te wā ka hinga te punaha immune, me te huringa o ngā pūtau aukati i roto i ngā pukupuku taketake e rua, ā, ka horapa ki ētahi atu wāhanga o te tinana. Ka taea e te punaha immune te mōhio ki ngā pūmua kei roto i ngā pūtau melanoma. Ko te mea nui, ko ngā maimoatanga e whakanui ana i te punaha raupatu, ā, kua whakaatuhia he huarahi mō te whawhai ki te mate pukupuku. Ahakoa he whanaketanga tata tonu te whakamahinga o ngā rongoā whakakaha i te melanoma, e tohu ana ngā rangahau tata nei ko te whakakotahi i ēnei rongoā me te chemotherapy, te immunotherapy, me ngā maimoatanga rapoi e whai ana i ngā hua pai ake. Heoi, ka taea e ēnei maimoatanga te whakaputa i te whānuitanga o ngā painga mō te tangata, ahakoa he iti noa te whakamahi. Mā te tiro whakamua, ko ngā huarahi e whai ake nei mō te rongoā i te melanoma, pērā i te whakamahi i ngā rongoā e aro ana ki ngā wāhi arowhai motuhake pērā i te PD1, me ngā rāau tātarā e whakatika ana i ngā ara BRAF me MEK.
Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compromised patients, the evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, the documented recognition of melanoma antigens by tumor-infiltrating T lymphocytes and, most important, evidence that melanoma responds to immunotherapy. The use of immunotherapy in the treatment of metastatic melanoma is a relatively late discovery for this malignancy. Recent studies have shown a significantly higher success rate with combination of immunotherapy and chemotherapy, radiotherapy, or targeted molecular therapy. Immunotherapy is associated to a panel of dysimmune toxicities called immune-related adverse events that can affect one or more organs and may limit its use. Future directions in the treatment of metastatic melanoma include immunotherapy with anti-PD1 antibodies or targeted therapy with BRAF and MEK inhibitors.
Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compromised patients, the evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, the documented recognition of melanoma antigens by tumor-infiltrating T lymphocytes and, most important, evidence that melanoma responds to immunotherapy. The use of immunotherapy in the treatment of metastatic melanoma is a relatively late discovery for this malignancy. Recent studies have shown a significantly higher success rate with combination of immunotherapy and chemotherapy, radiotherapy, or targeted molecular therapy. Immunotherapy is associated to a panel of dysimmune toxicities called immune-related adverse events that can affect one or more organs and may limit its use. Future directions in the treatment of metastatic melanoma include immunotherapy with anti-PD1 antibodies or targeted therapy with BRAF and MEK inhibitors.
